Clinical Trial Update: Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for liposomal amikacin for inhalation (LAI) evaluating treatment of Mycobacterium abscessus lung disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacteria Atypical
• Mycobacterium Abscessus Lung Disease
• Mycobacterium Infections Nontuberculous

Drugs mentioned

• Liposomal Amikacin for Inhalation (amikacin liposome inhalation suspension)

Snippet

Sponsor: Kevin Winthrop | Conditions: Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical | Phase 2 | Status: COMPLETED